Digipath's Orser and Denkin to Present at Hemp University

Event to Promote Hemp Business and Community

LAS VEGAS, March 21, 2019 /PRNewswire/ -- Digipath, Inc. (DIGP), a service-oriented independent testing laboratory, data and media firm focused on the developing cannabis and hemp markets, is pleased to announce that its CEO and Founder Todd Denkin and its Chief Science Officer Dr. Cindy Orser have been asked to present at the Hemp University symposium March 23, 2019 on the campus of Southern Oregon University. The event is hosted by Hemp, Inc. (HEMP) and brings together some of the leading minds in hemp to educate, support and build community for hemp farmers and entrepreneurs.

Dr. Orser and Mr. Denkin will host the session titled "The Evolving Science of Testing."  They will give an overview of Standard Operating Procedures for the 0.3% THC baseline compliance and testing for residual pesticides, microbes and terpene profiling.  

"We are excited to be a part of this tremendous event and to expand our leadership in hemp analytical and R & D testing," stated Todd Denkin, CEO and Founder, Digipath. "With our new hemp testing facility on the way in Oregon, this is a natural venue for us to participate. And with many of the attendees described as hemp and cannabis entrepreneurs and our new GroSciences division ready to help advance cannabis and hemp businesses of all variety, the timing is perfect."

"Anyone interested in advancing a business in hemp will certainly benefit from our presentation on testing and the array of experts that Hemp University has assembled," added Denkin.

For more information on Hemp University please visit: https://www.thehempuniversity.com/

About Digipath, Inc. & Digipath Labs, Inc.

Digipath, Inc. supports the cannabis industry's best practices for reliable testing, data acquisition, cannabis education and training, and brings unbiased cannabis news coverage to the cannabis industry. Digipath Labs provides pharmaceutical-grade analysis and testing to the cannabis industry to ensure producers, consumers, and patients know exactly what is in the cannabis they ingest and to help maximize the quality of its client's products through analysis, research, development, and standardization.

Digipath Investor Relations & Financial Media

Integrity Investor Relations
[email protected]
Toll Free: (888) 216-3595
www.IntegrityIR.com

Information about Forward-Looking Statements
This press release contains "forward-looking statements" that include information relating to future events. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management's good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in, or suggested by, the forward-looking statements. Important factors that could cause these differences include, but are not limited to: the Company's need for additional funding, the demand for the Company's products, governmental regulation of the cannabis industry, the Company's ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, growth in targeted markets, the adequacy of the Company's liquidity and financial strength to support its growth, and other risks that may be detailed from time-to-time in the Company's filings with the United States Securities and Exchange Commission. For a more detailed description of the risk factors and uncertainties affecting Digipath, please refer to the Company's recent Securities and Exchange Commission filings, which are available at www.sec.gov. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.